A Corewell Health study suggests that men who have longer prostatic urethras, the part of the urethra that travels through the prostate, may be at a higher risk of experiencing moderate, often chronic urinary side effects after receiving radiation for prostate cancer.
Researchers from UC Davis Comprehensive Cancer Center is testing a drug called niraparib (Zejula), given before prostate cancer surgery. Researchers think it could enable more personalized treatments—especially for men with prostate cancer that has specific DNA repair gene mutations.
